74663-96-0

Usage

Uses

Used in Flavoring Agents:
3-methyl-4-pyridinecarboxaldehyde is utilized as a flavoring agent in the food industry, where its caramel-like aroma enhances the sensory experience of various food products.
Used in Fragrance Ingredients:
In the cosmetic and personal care products industry, 3-methyl-4-pyridinecarboxaldehyde serves as a fragrance ingredient, contributing to the creation of appealing scents for a range of products.
Used in Pharmaceutical Synthesis:
3-methyl-4-pyridinecarboxaldehyde is employed as a key intermediate in the synthesis of pharmaceuticals, leveraging its reactive aldehyde group to form complex organic compounds for medicinal applications.
Used in Organic Compounds Synthesis:
Recognized for its versatility, 3-methyl-4-pyridinecarboxaldehyde is used in the synthesis of other organic compounds, highlighting its importance in advancing chemical research and development.

InChI:InChI=1/C7H7NO/c1-6-4-8-3-2-7(6)5-9/h2-5H,1H3

Upstream product

• 583-58-4 3,4-Lutidin 
• 88329-56-0 3,N-dimethylisonicotinanilide 
• 72990-37-5 3-chloro-4-pyridinecarboxyaldehyde 
• 823-96-1 Trimethylboroxine 

Downstream Products

• 222191-28-8 3-methyl-pyridine-4-carbaldehyde oxime 
• 1604771-53-0 C₁₇H₁₅F₃N₂O 
• 7584-05-6 3-methyl-4-cyanopyridine 

Relevant academic research and scientific papers

Meso-Pyridyl BODIPYs with tunable chemical, optical and electrochemical properties

A series of meso-pyridyl substituted BODIPY molecules has been synthesized, characterized and their optical and electrochemical properties compared. By utilizing ethanol and dichloromethane during the initial condensation reactions, there is a significant increase in the isolated yields compared to standard protocols. The properties of the highly fluorescent BODIPYs could be tuned by modifying the substituents of the pyridine, leading to pyridyl BODIPY as prospective ligands for future metal complexes. Furthermore, the presented BODIPY derivatives are shown to be applicable for fluorescence pH sensing over selective pH ranges.

Design, Synthesis, and Evaluation of the Highly Selective and Potent G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitor for the Potential Treatment of Heart Failure

A novel class of therapeutic drug candidates for heart failure, highly potent and selective GRK2 inhibitors, exhibit potentiation of β-adrenergic signaling in vitro studies. Hydrazone derivative 5 and 1,2,4-triazole derivative 24a were identified as hit compounds by HTS. New scaffold generation and SAR studies of all parts resulted in a 4-methyl-1,2,4-triazole derivative with an N-benzylcarboxamide moiety with highly potent activity toward GRK2 and selectivity over other kinases. In terms of subtype selectivity, these compounds showed enough selectivity against GRK1, 5, 6, and 7 with almost equipotent inhibition to GRK3. Our medicinal chemistry efforts led to the discovery of 115h (GRK2 IC50 = 18 nM), which was obtained the cocrystal structure with human GRK2 and an inhibitor of GRK2 that potentiates β-adrenergic receptor (βAR)-mediated cAMP accumulation and prevents internalization of βARs in β2AR-expressing HEK293 cells treated with isoproterenol. Therefore, 115h appears to be a novel class of therapeutic for heart failure treatment.

Copper-catalyzed selective oxygenation of methyl and benzyl substituents in pyridine with O2

A selective oxygenation of picolines and their derivatives has been achieved by usingasimple copper salt as a catalyst and molecular oxygen as an oxidant, where the α-position of the alkyl substituent is selectively oxidized to give the corresponding aldehydes or ketones. Addition of a catalytic amount of water enhances the catalytic activity, which could be attributed to the role of the proton donor to activate the substrates.

COMPOUNDS AND METHODS

The present invention relates to no vel retinoid-related orphan receptor gamma (RQRy) modulators and their use in the treatment of diseases mediated by RORy.

Optimization of the aromatase inhibitory activities of pyridylthiazole analogues of resveratrol

Aromatase is an established target not only for breast cancer chemotherapy, but also for breast cancer chemoprevention. The moderate and non-selective aromatase inhibitory activity of resveratrol (1) was improved about 100-fold by replacement of the ethyl

PYRIDAZINONE DERIVATIVES AND USE THEREOF AS P2X7 RECEPTOR INHIBITORS

Novel pyridazinone compounds of formula (I), which inhibit the purinergic P2X7 receptor and are useful for prevention, therapy and improvement of inflammatory and immunological diseases.

Substituted tetrahydropyridine derivatives acting on 5-HT receptors

PCT No. PCT/GB96/02763 Sec. 371 Date Apr. 29, 1998 Sec. 102(e) Date Apr. 29, 1998 PCT Filed Nov. 13, 1996 PCT Pub. No. WO97/18204 PCT Pub. Date May 22, 1997Compounds having formula I, or salts or prodrugs thereof: are selective agonists of the 5-HT1D alpha receptor and are useful in the treatment of migraine and associated conditions.

REACTIVITY OF METHYL DERIVATIVES OF NITROGENOUS HETEROCYCLES IN VAPOR-PHASE CATALYTIC OXIDATION

A study has been made of the reactivity of methylpyridines, methylpyrazines, and methylquinolines in oxidation in the vapor phase in the presence of β-VO(PO3)2.Relationships have been found between the overall reaction rates of heterocyclic compounds and the charge on the ring nitrogen, and between the partial oxidation rate and the charge on the ring carbon atom adjacent to the methyl group.The partial oxidation rate of methylpyridines is given to a first approximation by the Hammett-type expression lnWa = -3.5 + 4.6 Σ?, with a correlation coefficient of 0.93.